Numune Aliyeva

Numune Aliyeva

Auto-generated profile, based on publicly available information

Numune Aliyeva

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul, Turkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Lupus
Verified
Journal Article
Closed access
SDSelcuk Dasdemir
Selcuk Dasdemir
MYMehmet YILDIZ
Mehmet YILDIZ
DCDamla Celebi
Damla Celebi
SSSezgin Sahin
Sezgin Sahin
NANumune Aliyeva
Numune Aliyeva
OKOzgur Kasapcopur
Ozgur Kasapcopur
Objective: In this study, we aimed to screen 31 genes (C1QA, C1QB, C1QC, C1R, C1S, C2, C3, TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, DNASE1, DNASE1L3, PRKCD, ACP5, SLC7A7, IFIH1, TMEM173, ISG15, CYBB, FAS, FASLG, KRAS, NRAS, MAN2B1, PEPD, PTPN11, RAG2, and SHOC2), that we have categorized under the umbrella term “monogenic lupus” using a targeted next-generation sequencing (NGS) panel in 24 individuals with early-onset (≤10 years of age) systemic lupus erythematosus (SLE) and in 24 patients with late-onset (>10 years of age) disease. Methods: A total of 48 SLE patients (24 with disease onset ≤10 years of age and 24 with disease onset >10 years of age) were included. Patients with late-onset disease have been used as patient controls. Sequencing was carried out using 400 bp kit on the Ion S5 system. Results: Among the 48 patients, three had one pathogenic variant and 45 patients had at least one rare variant classified as benign, likely benign or variant of unknown significance (VUS). In all three patients with a pathogenic variant, the onset of disease was before 10 years of age. Two patients (they were siblings) carried C1QA homozygote pathogenic allele (p.Gln208Ter, rs121909581), and one patient carried PEPD heterozygote pathogenic allele (p.Arg184Gln, rs121917722). Conclusion: We demonstrated a pathogenic variant in our target gene panel with a frequency of 9.52% in patients with a disease onset ≤10 years of age. All patients with early-onset SLE phenotype, irrespective of a positive family history for SLE or parental consanguinity, should be scanned for a single-gene defect by a targeted gene panel sequencing. With the discovery of many single-gene defects and ongoing efforts to identify novel genes in SLE, similar gene panels including even more genes will possibly become more necessary and practical in the future.

29 March 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
MOMert Oztas
Mert Oztas
MBMurat Bektas
Murat Bektas
IKIlker Karacan
Ilker Karacan
NANumune Aliyeva
Numune Aliyeva
ADAyten Dag
Ayten Dag
SUSerdal Ugurlu
Serdal Ugurlu

1 January 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
AGAslihan Avanoglu Guler
Aslihan Avanoglu Guler
BÖBüşra Özçi̇mEn
Büşra Özçi̇mEn
MAMESUDE SEDA AYDOĞDU
MESUDE SEDA AYDOĞDU
ASAlper Sari
Alper Sari
ANAliyeva Numune
Aliyeva Numune
ATABDURRAHMAN TUFAN
ABDURRAHMAN TUFAN
The objective of this study is to evaluate the clinical presentations and adverse outcomes of Coronavirus Disease 2019 (COVID-19) in patients with systemic sclerosis (SSc) and assess the impact of SSc features on the clinical course of COVID-19.Materials and methods: In this multicenter, retrospective study, SSc patients with COVID-19 were included. Clinical features of SSc, along with detailed COVID-19 data, were extracted from medical records and patient interviews.Results: The study included 112 patients (mean age 51.4 ± 12.8 years; 90.2% female). SSc-associated interstitial lung disease (ILD) was evident in 57.1% of the patients. The findings revealed hospitalization in 25.5%, respiratory support in 16.3%, intensive care unit admission in 3.6%, and a mortality rate of 2.7% among SSc patients with COVID-19. Risk factors for respiratory failure, identified through univariate analysis, included ILD (OR: 7.49, 95% CI: 1.63–34.46), ≥1 comorbidity (OR: 4.55, 95% CI: 1.39–14.88), a higher physician global assessment score at the last outpatient visit (OR 2.73, 95% CI: 1.22–6.10), and the use of mycophenolate at the time of infection (OR: 5.16, 95 %CI: 1.79–14.99). Notably, ≥1 comorbidity emerged as the sole significant predictor of the need for respiratory support in COVID-19 (OR: 5.78, 95% CI: 1.14–29.23). In the early post-COVID-19 period, 17% of patients reported the progression of the Raynaud phenomenon, and 10.6% developed new digital ulcers. Furthermore, progression or new onset of dyspnea and cough were detected in 28.3% and 11.4% of patients, respectively.Conclusion: This study suggests a potential association between adverse outcomes of COVID-19 and SSc-related ILD, severe disease activity, and the use of mycophenolate. Additionally, it highlights that having comorbidities is an independent risk factor for the need for respiratory support in COVID-19 cases.

22 December 2021 in Ulusal Romatoloji Dergisi
Verified
Journal Article
Closed access
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
ÖPÖzlem Pehlivan
Özlem Pehlivan
NHNihat Hüseyinsinoğlu
Nihat Hüseyinsinoğlu
NANumune Aliyeva
Numune Aliyeva
SAShirkhan Amikishiyev
Shirkhan Amikishiyev
MÖMahmude Lale Öcal
Mahmude Lale Öcal